Johnson & Johnson stock trades near $268 after IMAAVY won U.S. FDA approval on August 24, 2026, whil

On 24 August 2026, Johnson & Johnson received U.S. FDA approval for IMAAVY (nipocalimab-aahu) to treat warm autoimmune hemolytic anemia in patients aged 12 and older who are currently or were previously treated with corticosteroids. This decision makes IMAAVY the first approved therapy for this rare, life‑threatening condition in steroid-treated patients, highlighting Johnson & Johnson’s push into targeted autoimmune treatments that spare broad immune suppression. We’ll now examine how...

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

Johnson & Johnson has outpaced the consumer staples sector over the past year, while analysts remain moderately bullish on the stock’s prospects.

Johnson & Johnson stock has delivered an 81.9% gain over the past three years, yet the valuation picture is split between an intrinsic value estimate that points to upside and market multiples that lean the other way. With recent approvals in key therapies alongside ongoing legal exposure, investors are weighing how much of Johnson & Johnson’s story is already reflected in the current share price. The 81.9% return over three years signals that Johnson & Johnson has rewarded longer term...

Johnson & Johnson stock has gained more than 50 percent over the past year, helped by a Q2 2026 shif

CAR-T therapies are transforming treatment for certain cancers and raising hopes for patients. Several approved therapies have delivered strong responses for patients with advanced blood cancers where conventional treatments have failed. It’s no wonder the CAR-T market is expanding rapidly. The global CAR-T therapy market is projected to grow from $2.69 billion in 2022 to […]

JNJ, MRK, and AMGN use AI to speed drug discovery, beat the market, and pay dividends. See the top AI healthcare pick for 2026.

Pharmaceutical giant Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer’s favorite stocks in the sector. Over the course of this year, the CNBC TV host has praised the firm on multiple occasions. Among the reasons that he has been optimistic about Johnson & Johnson (NYSE:JNJ) include the firm’s cancer drug portfolio and its Triple […]

Pharmaceutical giant Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer’s favorite stocks in the sector. Over the course of this year, the CNBC TV host has praised the firm on multiple occasions. Among the reasons that he has been optimistic about Johnson & Johnson (NYSE:JNJ) include the firm’s cancer drug portfolio and its Triple […]

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let

Johnson & Johnson and Merck are healthcare giants with dependable returns that weather economic downturns well.

Before mesothelioma claimed her life, Lynne Roy was a successful businesswoman and prominent resident of New Orleans. She developed the rare, aggressive form of cancer after decades of using the iconic talc-based product. She died in 2020, and after years of delay, this week, a Louisiana jury agreed that Johnson & Johnson was responsible for